The Association Between Platelet-Derived Growth Factor Receptor- Polymorphisms and Idiopathic Pulmonary Fibrosis

Karan, Burak Mugdat; ŞAHİN, Elif Sena; Kaya, Zehra; DURAN, Seren; GUNBATAR, HULYA

doi:10.5505/ejm.2023.03264

The Association Between Platelet-Derived Growth Factor Receptor- Polymorphisms and Idiopathic Pulmonary Fibrosis

Zehra KAYA, (Van Yüzüncü Yıl Üniversitesi Tıp Fakültesi Tıbbi Biyoloji Anabilim Dalı, Van, Türkiye)

Seren DURAN, (Van Yüzüncü Yıl Üniversitesi Tıp Fakültesi Tıbbi Biyoloji Anabilim Dalı, Van, Türkiye)

Hulya GUNBATAR, (Van Yüzüncü Yıl Üniversitesi Tıp Fakültesi Göğüs Hastalıkları Anabilim Dalı, Van, Türkiye)

Elif Sena ŞAHİN, (Van Yüzüncü Yıl Üniversitesi Tıp Fakültesi Tıbbi Biyoloji Anabilim Dalı, Van, Türkiye)

Burak Mugdat KARAN (Van Yüzüncü Yıl Üniversitesi Tıp Fakültesi Tıbbi Biyoloji Anabilim Dalı, Van, Türkiye)

Eastern Journal of Medicine

1 0

Yıl: 2023 Cilt: 28 Sayı: 1 Sayfa Aralığı: 139 - 145 Metin Dili: İngilizce DOI: 10.5505/ejm.2023.03264 İndeks Tarihi: 06-06-2023

The Association Between Platelet-Derived Growth Factor Receptor- Polymorphisms and Idiopathic Pulmonary Fibrosis

Öz:

Idiopathic pulmonary fibrosis (IPF) is a chronic interstiti al lung disease with a dismal prognosis. Platelet-derived growth factor (PDGF) receptor-β (PDGFR-β) are a receptor tyrosine kinase that PDGFs activate. It has been reported that inhibiting PDGFR -β in IPF patients can slow and improve disease progression. However, the effects of PDGFR-β on IPF remain unknown, and no studies on PDGFR-β polymorphisms for IPF have been conducted. The purpose of this study is to look into the relationship between PDGFR -β gene polymorphisms (rs246395, rs2302273, rs3828610, rs138008832) and IPF disease. The study included eleven patients with IPF and twelve healthy controls. DNA was isolated from blood samples taken from all participants, and genotyping was performed using a StepOne plus real time PCR device. There was no statistically significant difference between the variables (age, gender, smoking, alcohol, and gastroesophageal reflux (GER). There was no statistically significant difference between the patient and control groups in the allele and genotype fre quencies of these polymorphisms. Furthermore, no statistically significant difference was found between patients' smoking, forced vital capacity (FVC) (normal, low), and GER data, as well as PDGFR-β variants (rs246395, rs2302273, rs3828610 and rs138008832). In order to determine the relationship between PDGFR-β gene polymorphisms and the risk of IPF, larger studies with more participants are required.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Behr J. The diagnosis and treatment of idiopathic pulmonary fibrosis. Dtsch Arztebl Int. 2013 Dec 23; 110: 875-881.
2. Waters DW, Blokland KEC, Pathinayake PS, et al. Fibroblast senescence in the pathology of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2018; 315: L162-L172.
3. Martinez FJ, Collard HR, Pardo A, Raghu G, Richeldi L, Selman M. et al. Idiopathic pulmonary fibrosis. Nat Rev Dis Primers 2017; 20:3: 17074.
4. Selman M, Pardo A. The leading role of epithelial cells in the pathogenesis of idiopathic pulmonary fibrosis. Cell Signal. 2020; 66: 109482
5. Spagnolo P, Lee JS, Sverzellati N, Rossi G, Cottin V. The Lung in Rheumatoid Arthritis: Focus on Interstitial Lung Disease. Arthritis Rheumatol 2018; 70: 1544-1554.
6. Shioya M, Otsuka M, Yamada G, Umeda Y, Ikeda K, Nishikiori H, Kuronuma K, Chiba H, Takahashi H. Poorer Prognosis of Idiopathic Pleuroparenchymal Fibroelastosis Compared with Idiopathic Pulmonary Fibrosis in Advanced Stage. Can Respir J 2018; 2018: 6043053.
7. Phan THG, Paliogiannis P, Nasrallah GK, et al. Emerging cellular and molecular determinants of idiopathic pulmonary fibrosis. Cell Mol Life Sci 2021; 78: 2031-2057.
8. King TE Jr., Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011; 378: 1949-1961.
9. Inomata M, Nishioka Y, Azuma A. Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis. Core Evid 2015; 10: 89-98.
10. Ouyang L, Zhang K, Chen J, Wang J, Huang H. Roles of platelet-derived growth factor in vascular calcification. J Cell Physiol 2018; 233: 2804-2814.
11. Grimminger F, Günther A, Vancheri C. The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis. Eur Respir J. 2015; 45: 1426-1433.
12. Kanzaki R,Ose N, Kawamura T, Funaki S, Shintani Y, Minami M, et al. Stromal PDGFR-β expression is associated with postoperative survival of non-small cell lung cancer patients receiving preoperative chemo-or chemoradiotherapy follawed by surgery. World Journal of Surgery. 2018; volume 42, Issue 9, pp- 2879-86
13. Kishi M, Aono Y, Sato S, et al. Blockade of platelet-derived growth factor receptor-β, not receptor-α ameliorates bleomycin-induced pulmonary fibrosis in mice. PLoS One. 2018;13(12):e0209786.
14. Estevez-Garcia P, Castaño A, Martin AC, Lopez- Rios F, Iglesias J, Muñoz-Galván S. et al. PDGFRα/β and VEGFR2 polymorphisms in colorectal cancer: incidence and implications in clinical outcome. BMC Cancer 2012; 12; 12: 514.
15. Garrigós C, Espinosa M, Salinas A, et al. Single nucleotide polymorphisms as prognostic and predictive biomarkers in renal cell carcinoma. Oncotarget 2017; 8: 106551-106564.
16. Wang X, Zhang Z, Liu W, Xiong Y, Sun W, Huang X, et al. Impacts and interactions of PDGFR-β, MMP-3, TIMP-2 and RNF213 polymorphims on the risk of moyamoya disease in han Chinese human subjects. Gene. 2013;1 0[526(2]:437-42
17. Sanchez-Contreras M, Baker MC, Finch NA, et al. Genetic screening and functional characterization of PDGFRB mutations associated with basal ganglia calcification of unknown etiology. Hum Mutat. 2014;35(8):964-971.
18. Okumuş G. Türk Toraks Derneği İdiyopatik Pulmoner Fibrozis (İpf) Tanı Ve Tedavi Uzlaşı Raporu. Okumuş G, Bingöl Z, editörler. İdiyopatik Pulmoner Fibrozis (İpf) Tanı Ve Tedavi Uzlaşı Raporu. Ankara; Bilimsel Tıp Yayınevi; 2018.
19. Hintze, J. (2011). PASS 11. NCSS, LLC. Kaysville, Utah, USA. www.ncss.com.
20. Newcombe, R. G. 1998. 'Two-Sided Confidence Intervals for the Single Proportion: Comparison of Seven Methods.' Statistics in Medicine, 17, pp. 857-872.
21. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F et al., American Thoracic Society ERSJRS, Latin American Thoracic S. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. American journal of respiratory and critical care medicine 2018; 198: e44-e68.
22. Lee JS, Ryu JH, Elicker BM, et al. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184: 1390-1394.
23. Barratt SL, Creamer A, Hayton C, Chaudhuri N. Idiopathic Pulmonary Fibrosis (IPF): An Overview. J Clin Med 2018; 7: 201.
24. Zaman T, Lee JS. Risk factors for the development of idiopathic pulmonary fibrosis: A review. Curr Pulmonol Rep 2018; 7: 118-125.
25. Sack C, Raghu G. Idiopathic pulmonary fibrosis: unmasking cryptogenic environmental factors. Eur Respir J 2019; 53: 1801699
26. Krishna R, Chapman K, Ullah S. Idiopathic Pulmonary Fibrosis. In: StatPearls. Treasure Island (FL) StatPearls Publishing; 2022 Jan-. Bookshelf ID: NBK448162PMID: 28846333
27. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183: 431-440.
28. Zhou LL, Wang M, Liu F, et al. Cigarette smoking aggravates bleomycin-induced experimental pulmonary fibrosis. Toxicol Lett 2019; 303: 1-8.
29. Wollin L, Wex E, Pautsch A, Schnapp G, Hostettler KE, Stowasser S, Kolb M. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.Eur Respir J 2015; 45: 1434- 45.
30. Qian Y, Yu L, Zhang XH, Yuan ZQ, Zhao P, Sun LN et al. Genetic Polymorphism on the Pharmacokinetics and Pharmacodynamics of Platelet-derived Growth Factor Receptor (PDGFR) Kinase Inhibitors.Curr Drug Metab. 2018; 19: 1168-1181.

APA	Kaya Z, DURAN S, GUNBATAR H, ŞAHİN E, Karan B (2023). The Association Between Platelet-Derived Growth Factor Receptor- Polymorphisms and Idiopathic Pulmonary Fibrosis. , 139 - 145. 10.5505/ejm.2023.03264
Chicago	Kaya Zehra,DURAN Seren,GUNBATAR HULYA,ŞAHİN Elif Sena,Karan Burak Mugdat The Association Between Platelet-Derived Growth Factor Receptor- Polymorphisms and Idiopathic Pulmonary Fibrosis. (2023): 139 - 145. 10.5505/ejm.2023.03264
MLA	Kaya Zehra,DURAN Seren,GUNBATAR HULYA,ŞAHİN Elif Sena,Karan Burak Mugdat The Association Between Platelet-Derived Growth Factor Receptor- Polymorphisms and Idiopathic Pulmonary Fibrosis. , 2023, ss.139 - 145. 10.5505/ejm.2023.03264
AMA	Kaya Z,DURAN S,GUNBATAR H,ŞAHİN E,Karan B The Association Between Platelet-Derived Growth Factor Receptor- Polymorphisms and Idiopathic Pulmonary Fibrosis. . 2023; 139 - 145. 10.5505/ejm.2023.03264
Vancouver	Kaya Z,DURAN S,GUNBATAR H,ŞAHİN E,Karan B The Association Between Platelet-Derived Growth Factor Receptor- Polymorphisms and Idiopathic Pulmonary Fibrosis. . 2023; 139 - 145. 10.5505/ejm.2023.03264
IEEE	Kaya Z,DURAN S,GUNBATAR H,ŞAHİN E,Karan B "The Association Between Platelet-Derived Growth Factor Receptor- Polymorphisms and Idiopathic Pulmonary Fibrosis." , ss.139 - 145, 2023. 10.5505/ejm.2023.03264
ISNAD	Kaya, Zehra vd. "The Association Between Platelet-Derived Growth Factor Receptor- Polymorphisms and Idiopathic Pulmonary Fibrosis". (2023), 139-145. https://doi.org/10.5505/ejm.2023.03264

APA	Kaya Z, DURAN S, GUNBATAR H, ŞAHİN E, Karan B (2023). The Association Between Platelet-Derived Growth Factor Receptor- Polymorphisms and Idiopathic Pulmonary Fibrosis. Eastern Journal of Medicine, 28(1), 139 - 145. 10.5505/ejm.2023.03264
Chicago	Kaya Zehra,DURAN Seren,GUNBATAR HULYA,ŞAHİN Elif Sena,Karan Burak Mugdat The Association Between Platelet-Derived Growth Factor Receptor- Polymorphisms and Idiopathic Pulmonary Fibrosis. Eastern Journal of Medicine 28, no.1 (2023): 139 - 145. 10.5505/ejm.2023.03264
MLA	Kaya Zehra,DURAN Seren,GUNBATAR HULYA,ŞAHİN Elif Sena,Karan Burak Mugdat The Association Between Platelet-Derived Growth Factor Receptor- Polymorphisms and Idiopathic Pulmonary Fibrosis. Eastern Journal of Medicine, vol.28, no.1, 2023, ss.139 - 145. 10.5505/ejm.2023.03264
AMA	Kaya Z,DURAN S,GUNBATAR H,ŞAHİN E,Karan B The Association Between Platelet-Derived Growth Factor Receptor- Polymorphisms and Idiopathic Pulmonary Fibrosis. Eastern Journal of Medicine. 2023; 28(1): 139 - 145. 10.5505/ejm.2023.03264
Vancouver	Kaya Z,DURAN S,GUNBATAR H,ŞAHİN E,Karan B The Association Between Platelet-Derived Growth Factor Receptor- Polymorphisms and Idiopathic Pulmonary Fibrosis. Eastern Journal of Medicine. 2023; 28(1): 139 - 145. 10.5505/ejm.2023.03264
IEEE	Kaya Z,DURAN S,GUNBATAR H,ŞAHİN E,Karan B "The Association Between Platelet-Derived Growth Factor Receptor- Polymorphisms and Idiopathic Pulmonary Fibrosis." Eastern Journal of Medicine, 28, ss.139 - 145, 2023. 10.5505/ejm.2023.03264
ISNAD	Kaya, Zehra vd. "The Association Between Platelet-Derived Growth Factor Receptor- Polymorphisms and Idiopathic Pulmonary Fibrosis". Eastern Journal of Medicine 28/1 (2023), 139-145. https://doi.org/10.5505/ejm.2023.03264